Navigation Links
Pleiad Devices Selects OmniComm Systems as their eClinical Solutions Provider
Date:8/25/2009

FORT LAUDERDALE, Fla., Aug. 25 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced today that their EDC tool, TrialMaster(TM), has been selected by Pleiad, Inc., a Cambridge, Massachusetts based Contract Research Organization (CRO) with European operations in the U.K., to provide eClinical services to its customers. Pleiad's investment will provide it with the products and services to manage two upcoming studies investigating the use of ophthalmic medical devices. This partnership is expected to generate more than $1 million to OmniComm over the next few years. Pleiad has worked with the TrialMaster EDC tool since April 2008 under OmniComm's CRO Preferred Program, and is now transitioning to a Technology Transfer model in order to provide greater value to its customers engaged in these important clinical trials.

"We are pleased to once again be collaborating with Pleiad, as the exposure generated from working closely on a continual basis with such a specialized, internationally renowned CRO will undoubtedly raise our profile within the international clinical community," commented Stephen Johnson, OmniComm's COO. "We expect that as we continue to work with well respected, high profile organizations such as Pleiad, we will continue to attract companies of an equally high caliber to our dramatically enhanced service offering. We feel that we can offer organizations engaged in clinical research a significant advantage over their peers with our highly specialized portfolio of eClinical solutions designed to greatly simplify the clinical process."

"TrialMaster has been an essential option for us to provide to our customers. Much is made about the importance of subject compliance in clinical research, but we find that study coordinator 'compliance' is also very critical. The TrialMaster EDC system is very intuitive, so the study coordinators with whom we work have little problem in getting their work completed within the allocated time," stated Stephen Brandao, Pleiad's Vice President of Business Development. "We find that OmniComm is an attentive partner, very much in tune with the needs of our business. Our team anticipates collaborating with them on future opportunities."

About Pleiad

Pleiad, Inc. is a clinical CRO (contract research organization) that specializes in expertly assisting medical device, combination, women's health, and ophthalmic product manufacturers meet the clinical, quality, safety and regulatory requirements of the product development process. Their work encompasses the progression from the conceptual and developmental stages to post-marketing trials, offering regulatory support, clinical trial management, and safety monitoring services.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    CONTACT:
    Catherine Lemercier
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    clemercier@omnicomm.com

    Stephen Johnson at: + 1 954-377-1726

    Gary Nash
    CEOcast, Inc. for OmniComm
    212-732-4300
    gnash@ceocast.com


'/>"/>
SOURCE OmniComm Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frost & Sullivan: Malaysia Diagnostics and Devices Industry Outlook 2009
2. Inaugural Medical Device Connectivity Conference & Exhibition to Focus on Connecting Medical Devices to People, Workflow and Information Systems
3. CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices
4. Minnesotans to Keynote Materials for Medical Devices Conference
5. Following CMS Cuts to Reimbursement for Medical Errors, New Devices Aimed at Reducing Nosocomial Infections Emerge
6. European Health Care Institutions Forced to Select Lower-Priced Interventional Cardiology Devices
7. Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare, States Frost & Sullivan
8. Materials and Processes for Medical Devices Event Brings Clinicians, Engineers, Designers Together
9. Broncus Technologies Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market, According to Millennium Research Group
10. White Paper Explains Package Validation Requirements For Medical Devices & Combinatory Products
11. MPR Drug Database Available as a Free Download for Mobile Devices, Including BlackBerry and Palm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 2017 , ... ProRehab Physical Therapy (PRPT) is ... therapy provider for Derby City CrossFit, effective immediately. , In addition to treating ... effectively as possible, ProRehab’s sports physical therapists will work with athletes to maximize ...
(Date:4/25/2017)... ... 2017 , ... A recent report from the Wisconsin Institute ... 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools participating ... student test score performance, the report’s limited analyses fail to provide answers as ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... ... 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of ... I focus on preventative care with all my patients to alleviate possible future issues. I ... free to contact my office and my trained staff will assist you in any way ...
(Date:4/25/2017)... ... 25, 2017 , ... Vetoquinol USA® , a world-class ... part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in ... immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
Breaking Medicine Technology: